Targeting of a Mutant Plasminogen Activator to Circulating Red Blood Cells for Prophylactic Fibrinolysis

Chemical coupling to carrier red blood cells (RBCs) converts tissue type plasminogen activator (tPA) from a problematic therapeutic into a safe agent for thromboprophylaxis. The goal of this study was to develop a more clinically relevant recombinant biotherapeutic by fusing a mutant tPA with a single-chain antibody fragment (scFv) with specificity for glycophorin A (GPA) on mouse RBCs. The fusion construct (anti-GPA scFv/PA) bound specifically to mouse but not human RBCs and activated plasminogen; this led to rapid and stable attachment of up to 30,000 copies of anti-GPA scFv/PA per mouse RBC that were thereby endowed with high fibrinolytic activity. Binding of anti-GPA scFv/PA neither caused RBC aggregation, hemolysis, uptake in capillary-rich lungs or in the reticuloendothelial system nor otherwise altered the circulation of RBCs. Over 40% of labeled anti-GPA scFv/PA injected in mice bound to RBC, which markedly prolonged its intravascular circulation and fibrinolytic activity compared with its nontargeted PA counterpart, anti-GPA scFv/PA, but not its nontargeted PA analog, prevented thrombotic occlusion in FeCl3 models of vascular injury. These results provide proof-of-principle for the development of a recombinant PA variant that binds to circulating RBC and provides thromboprophylaxis by use of a clinically relevant approach.

[1]  I. Weissman,et al.  The monoclonal antibody TER‐119 recognizes a molecule associated with glycophorin A and specifically marks the late stages of murine erythroid lineage , 2000, British journal of haematology.

[2]  V. Muzykantov,et al.  Red Blood Cells-Coupled tPA Prevents Impairment of Cerebral Vasodilatory Responses and Tissue Injury in Pediatric Cerebral Hypoxia/Ischemia through Inhibition of ERK MAPK Activation , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[3]  J. Atkinson,et al.  ScFv-mediated in vivo targeting of DAF to erythrocytes inhibits lysis by complement. , 2004, Molecular immunology.

[4]  V. Muzykantov,et al.  Prophylactic thrombolysis by thrombin-activated latent prourokinase targeted to PECAM-1 in the pulmonary vasculature. , 2008, Blood.

[5]  Vladimir R Muzykantov,et al.  Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis. , 2006, Blood.

[6]  V. Marchesi,et al.  Subunit structure of human erythrocyte glycophorin A. , 1976, Biochemistry.

[7]  V. Muzykantov,et al.  Endothelial targeting of a recombinant construct fusing a PECAM-1 single-chain variable antibody fragment (scFv) with prourokinase facilitates prophylactic thrombolysis in the pulmonary vasculature. , 2005, Blood.

[8]  D. Rijken,et al.  Superficial accumulation of plasminogen during plasma clot lysis. , 1995, Circulation.

[9]  S. Lipton,et al.  Tissue plasminogen activator (tPA) increase neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice , 1998, Nature Medicine.

[10]  Vladimir R Muzykantov,et al.  Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes , 2003, Nature Biotechnology.

[11]  E. Topol,et al.  A multicenter, randomized, placebo-controlled trial of a new form of intravenous recombinant tissue-type plasminogen activator (activase) in acute myocardial infarction. , 1987, Journal of the American College of Cardiology.

[12]  D. Rijken,et al.  Clot penetration and fibrin binding of amediplase,a chimeric plasminogen activator (K2 tu-PA). , 2003, Thrombosis and haemostasis.

[13]  R. Nagel,et al.  Molecular cloning and expression of a chloride channel-associated protein pICln in human young red blood cells: association with actin. , 1997, The Biochemical journal.

[14]  F. Joubert,et al.  Purification of human tissue plasminogen activator with Erythrina trypsin inhibitor. , 1984, The Journal of biological chemistry.

[15]  D. Collen.  Fibrin-selective thrombolytic therapy for acute myocardial infarction. , 1996, Circulation.

[16]  Vladimir R Muzykantov,et al.  The Glycocalyx Protects Erythrocyte-Bound Tissue-Type Plasminogen Activator from Enzymatic Inhibition , 2007, Journal of Pharmacology and Experimental Therapeutics.

[17]  P. Lyden,et al.  Comparison of TNK With Wild-Type Tissue Plasminogen Activator in a Rabbit Embolic Stroke Model , 2001, Stroke.

[18]  R. Rudolph,et al.  Biochemical properties of the kringle 2 and protease domains are maintained in the refolded t-PA deletion variant BM 06.022. , 1992, Protein engineering.

[19]  A. Schwartz,et al.  Two receptor systems are involved in the plasma clearance of tissue-type plasminogen activator (t-PA) in vivo. , 1995, The Journal of clinical investigation.

[20]  R. Rudolph,et al.  Pharmacokinetic properties of an Escherichia-coli-produced recombinant plasminogen activator (BM 06.022) in rabbits. , 1991, Thrombosis research.

[21]  D. Combs,et al.  Pharmacokinetics and Pharmacodynamics of Tenecteplase in Fibrinolytic Therapy of Acute Myocardial Infarction , 2002, Clinical pharmacokinetics.

[22]  B. Zlokovic.  Antithrombotic, procoagulant, and fibrinolytic mechanisms in cerebral circulation: implications for brain injury and protection. , 1997, Neurosurgical focus.

[23]  M. Yepes,et al.  Is Magnetic Resonance Spectroscopy Superior to Conventional Diagnostic Tools in Hypoxic‐Ischemic Encephalopathy? , 2004, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[24]  S. Papson,et al.  “Model” , 1981 .

[25]  D. Birmingham,et al.  CR1 and CR1‐like: the primate immune adherence receptors , 2001, Immunological reviews.

[26]  C. Reilly,et al.  Both circulating and clot-bound plasminogen activator inhibitor-1 inhibit endogenous fibrinolysis in the rat. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[27]  J. W. Cheng,et al.  Tenecteplase: a review. , 2001, Clinical therapeutics.

[28]  G. Clagett,et al.  Antithrombotic therapy in peripheral arterial occlusive disease. , 1992, Chest.

[29]  J. Atkinson,et al.  In Vivo Correction of Complement Regulatory Protein Deficiency with an Inhibitor Targeting the Red Blood Cell Membrane1 , 2005, The Journal of Immunology.

[30]  Vladimir R Muzykantov,et al.  Blood Clearance and Activity of Erythrocyte-Coupled Fibrinolytics , 2005, Journal of Pharmacology and Experimental Therapeutics.

[31]  G. Matthyssens,et al.  Pharmacokinetic and thrombolytic properties of chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody fused to single-chain urokinase. , 1993 .

[32]  Scott L Diamond,et al.  Fibrin Affinity of Erythrocyte-Coupled Tissue-Type Plasminogen Activators Endures Hemodynamic Forces and Enhances Fibrinolysis in Vivo , 2006, Journal of Pharmacology and Experimental Therapeutics.

[33]  G. Matthyssens,et al.  Pharmacokinetic and thrombolytic properties of chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody fused to single-chain urokinase. , 1993, Blood.

[34]  E. Haber,et al.  Enhanced thrombolytic and antithrombotic potency of a fibrin-targeted plasminogen activator in baboons. , 1996, Circulation.

[35]  D. Atochin,et al.  Cerebrovascular Thromboprophylaxis in Mice by Erythrocyte-Coupled Tissue-Type Plasminogen Activator , 2008, Circulation.

[36]  Vladimir P Torchilin,et al.  Liposomes for targeted delivery of antithrombotic drugs. , 2008, Expert opinion on drug delivery.

[37]  Eng H. Lo,et al.  Neurological diseases: Mechanisms, challenges and opportunities in stroke , 2003, Nature Reviews Neuroscience.

[38]  R. Marchant,et al.  RGD-modified liposomes targeted to activated platelets as a potential vascular drug delivery system , 2004, Thrombosis and Haemostasis.